

# Study Group – R/R ALL

There is still insufficient data about the proper bridging therapy management before CAR T cell therapy. This study group strives to understand the impact of low- and highintensity bridging regimens on a variety of outcome parameters.

**Speaker:** Prof. Dr. Tobias Feuchtinger, LMU Munich **Presentation:** Dr. Maike Breidenbach, LMU Munich

Concept & Achievements

**Retrospective Analysis of Bridging Therapy Prior to AntiCD19 CAR T Cell Therapy** 

The R/R ALL group attempts to develop a guideline for the proper management of bridging therapy prior to antiCD19 CAR T cell therapy through a multinational, retrospective data collection and consensus workshops. We defined the following milestones:

- development of a guidance for multimodal bridging » therapy
- set-up of registry for children and young adults with R/R » ALL in Bavaria and beyond
- analysis of markers for later response to immunotherapy » approaches
- preparing and defining a future GCP clinical trial and set-» up of structures for the conduction of the trial

#### Milestone 1: Guidance for multimodal bridging therapy

In October 2022, we set up a **consensus workshop** on bridging therapy prior to CAR T cell therapy for R/R ALL patients. Experts from Germany, Austria and Switzerland were invited to discuss. This led to a **publication**, which is currently **under revision**.

### Milestones 2 and 3: Set-up of registry for children and young adults with R/R ALL and analysis of markers for later response to immunotherapy

See graphical abstract (Figure 1). Performed treatments were classified into the categories 1) no systemic therapy, 2) lowintensity and 3) high-intensity therapy (Figure 2). Data analysis is almost done and results are shortly before publication.

#### Milestone 4: Preparing and defining a future GCP clinical trial and set-up of structures for the conduction

Due to the fact that we included further sites beyond Bavaria,





Figure 1: graphical abstract \*


#### Major results of the registry:

- patients receiving a high-intensity bridging therapy had a significantly higher tumor burden at time point of eligibility defined by blasts in bone marrow and by measurement of minimal residual disease (MRD) tumor burden within the three groups
- converged over the time of bridging therapy (Figure 3)
- at time of lymphodepletion, patients in the high-intensity group showed a significantly lower performance status than patients in the low-intensity/no systemic therapy group ... and suffered significantly more often from bacterial adverse events and mucositis overall and disease-free survival did not differ significantly between groups.




100

Figure 2: distribution of bridging therapies



we first focused on the execution and analysis of the large-scale registry. Hence, we have not started with this milestone, yet. Planning a GCP trial will has to rely on the registry results.

Future Milestones



#### preliminary data

## Data publication until end of 2023

**Preparation of a GCP-study** »

Authors: Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Müller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Krauß, Arend von Stackelberg, Semjon Willier, Christina Peters and Tobias Feuchtinger

\*The Figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license. Further funding of registry: Servier Germany.





Bayerisches Staatsministerium für Wissenschaft und Kunst